Develops pharmaceutical solutions using a platform for oral delivery of therapeutic proteins, and invests in healthcare and life sciences companies.
10-K for FY2025, filed Mar 26, 2026
The company received payments under its HTIT technology license; the remaining deferred amount counted as revenue after HTIT waived claims in connection with the joint venture agreement.
10-K for FY2025, filed Mar 26, 2026On November 30, 2015, the Company entered into a Technology License Agreement, with HTIT and on December 21, 2015, the parties entered into…View ↗
As of December 31, 2024, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through…View ↗
In the year ended December 31, 2025, the Company recognized revenue associated with the HTIT License Agreement in an amount of $2,000…View ↗
$2M
10-K for FY2025, filed Mar 26, 2026
$2M ↗
HTIT was the licensee for Oramed’s oral insulin capsule, with rights to commercialize it in China, Macau and Hong Kong.
10-K for FY2022, filed Mar 6, 2023On November 30, 2015, we entered into a Technology License Agreement, or TLA, with Hefei Tianhui Incubator of Technologies Co., Ltd., or…View ↗
Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$9.2M.
10-Q for Q3 FY2026, filed Nov 12, 2026
$18.4MView ↗
8-K, filed Mar 31, 2026
As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on January 14, 2026…View ↗
Shrinking. Revenue fell 26% in 4 years, from $2.7M in FY2021 to $2M in FY2025, about 7% a year.
Strategic investments
The latest report adds strategic investing alongside pharmaceutical research and development, including capital allocation to healthcare and life sciences companies.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 26, 2026We are currently a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology…View ↗
We are a pharmaceutical company engaged in the research and development of innovative pharmaceutical solutions with a technology platform…View ↗
Loading...